IL6 and congenital rubella syndrome: To date, the National Comprehensive Cancer Network (NCCN) guidelines (version 1 in 2020) suggest that corticosteroids are preferred for cases with persistent refractory hypotension after IL-6 blockade and in the presence of severe CRS.